Hepatitis C Virus RNA Profiles in Chronically Infected Individuals: Do They Relate to Disease Activity?
|
|
- Beverly Russell
- 5 years ago
- Views:
Transcription
1 Hepatitis C Virus RNA Profiles in Chronically Infected Individuals: Do They Relate to Disease Activity? PATRIZIA PONTISSO, 1 GIORGIO BELLATI, 2 MAURIZIA BRUNETTO, 2 LILIANA EMELLO, 1 GUIDO COLLOREDO, 2 ROSELLINA DI STEFANO, 3 MASSIMO NICOLETTI, 1 MARIA GRAZIA RUMI, 4 MARIA GRAZIA RUVOLETTO, 1 ROBERTA SOFFREDINI, 4 LILLI MARIO VALENZA, 3 AND GIUSEPPE COLUCCI 5 Fluctuations of hepatitis C virus (HCV)-RNA serum levels were monitored in a multicenter study in 76 chronic HCV carriers who had been followed longitudinally without receiving antiviral therapy to assess their relation with the course of liver disease activity. Forty-four patients had normal transaminases over more than 2 years, while 32 additional patients had fluctuating levels. Viral load was measured in serial serum samples prospectively collected for 10 to 12 months in 54 patients and in sera stored yearly up to 8 years in an additional 22 patients. In patients tested monthly, a lesser extent of fluctuations was detected in cases with constantly normal transaminases as compared with those with fluctuating transaminases. In the former group, the mean difference between maximum and minimum values observed in each individual patient was 0.7 Log, while in the latter group, it was 1.3 Log (P.0004). Most of these patients experienced, on average, three peaks of viremia over 1 year. The range of variation observed upon yearly testing was between 0.2 and 2.2 Log and did not reach statistical significance between the two groups. In conclusion, a careful viral replication profile can be achieved only by monthly testing, because longer time intervals could miss viremia fluctuations. HCV-RNA levels are more stable in asymptomatic HCV carriers than in patients with biochemical activity of liver disease. (HEPATOLOGY 1999;29: ) Chronic infection with hepatitis C virus (HCV) is characterized by persistent viremia. HCV RNA is usually detected in serum by sensitive polymerase chain reaction (PCR)-based techniques and has become a useful tool for diagnosis and monitoring. Besides methods for qualitative detection of viremia, a number of procedures to quantify serum HCV RNA have been developed, including end-point dilution PCR, 1 competitive PCR, 2,3 isothermal nucleic acid amplification, 4 Abbreviations: HCV, hepatitis C virus; PCR, polymerase chain reaction; ALT, alanine aminotransferase. From the 1 Department of Clinical and Experimental Medicine, University of Padova, Italy; 2 Division of Gastroenterology, Molinette Hospital, Torino, Italy; 3 Institute of Internal Medicine, University of Palermo, Italy; 4 Department of Internal Medicine, University of Milano, Italy; and 5 Roche Molecular Systems, Basel, Switzerland. Received June 12, 1998; accepted October 2, Address reprint requests to: Patrizia Pontisso, M.D., Dipartimento di Medicina Clinica e Sperimentale Clinica Medica 5, Università di Padova, Via Giustiniani, Padova, Italy. patrizia@ux1.unipd.it; fax: Copyright 1999 by the American Association for the Study of Liver Diseases /99/ $3.00/0 585 and signal-amplification branched DNA. 5 Routine use of these techniques in a wide clinical setting is hampered by problems of specificity and sensitivity, lack of reproducibility, poor standardization, and high cost. 6 Recently, methods for quantitative assessment of HCV-RNA levels have become commercially available and are being extensively evaluated in clinical studies, particularly in patients treated with interferons and antivirals. 7 Little is known about viral kinetics in untreated patients, because most evaluations of the level of viremia are based on single determinations. If wide spontaneous fluctuations occur, they could mimic treatment-induced effects or lead to under- or overestimate baseline values. In a few published studies, different time intervals have been evaluated and discordant conclusions have been reported. Either trivial or consistent differences of viral load over time have been described after observation periods ranging from days to months To assess the spontaneous behavior of serum HCV-RNA levels over a reasonable length of time upon close observation, we monitored chronic HCV carriers who had been followed longitudinally without receiving any antiviral therapy and then analyzed their patterns of virus replication in relation to biochemical and histological activity of liver disease. PATIENTS AND METHODS Patients. Seventy-six chronic carriers of HCV were evaluated in a multicenter study (the HEPCCOM Italian Study) in which collection and virological analysis were performed by each participating Center, including the Division of Gastroenterology, Molinette Hospital-Torino, the Department of Internal Medicine-University of Milano, the Department of Clinical and Experimental Medicine- University of Padova, and the Institute of Internal Medicine- University of Palermo. The study population included 44 patients with constantly normal alanine aminotransferase (ALT) values since at least 6 months before enrollment in the study and during a follow-up period lasting for more than 2 years (mean follow-up, 3 years; range, 2-8 years), and 32 additional patients with fluctuating ALT. There were 42 males and 34 females, with a median age of 53 years (range, years). All were HCV-RNA positive by qualitative PCR before entering the study. None of the patients had evidence of ongoing hepatitis B virus or human immunodeficiency virus infection; current alcohol and/or drug abuse or metabolic disorders were also excluded in all patients. None of the patients underwent antiviral treatment during the time of the study. Serial serum samples collected yearly over a period of several years were available for 22 patients (median samples/patient, 4 samples; range, 3-8 samples/patient). In 54 additional cases, monthly serum and plasma samples were obtained during a prospective follow-up period, lasting 10 2 months (mean SD). All samples were collected in sterile conditions, centrifuged, and stored in 500-µL
2 586 PONTISSO ET AL. HEPATOLOGY February 1999 aliquots at 80 C within 3 hours after withdrawal. Only unthawed samples were used for HCV-RNA measurements. In 49 patients, liver biopsy was obtained just before or during the time of the study and was consistent with minimal liver lesions in 3 patients, mild chronic hepatitis in 25 patients, moderate chronic hepatitis in 20 patients, and severe hepatitis in 1 patient. Viral Markers. Anti-HCV was determined by commercially available second-generation enzyme-linked immunosorbent assay kits (Ortho Diagnostics, Raritan, NJ) and confirmed by radioimmunoblot assay 2 or 3. Hepatitis B surface antigen and anti human immunodeficiency virus were detected by enzyme-linked immunosorbent assay (Abbott Diagnostics, North Chicago, IL). Qualitative HCV-RNA Determination. To assess HCV RNA in serum, either the commercially available qualitative Amplicor HCV assay (Roche Molecular Systems, Branchburg, NJ) or home-made reversetranscription nested PCR were performed. The former assay showed sensitivity and specificity similar to in-house reverse-transcription PCR in a large confirmatory study 13 to a cut-off level of 10 3 genomes/ml. HCV Genotype Determination. The HCV genotype was determined by InnoLipa assay (Innogenetics, Gent, Belgium) or by a previously published protocol 14 that has been validated by direct sequencing and by InnoLipa assay. 15 Briefly, PCR-amplified products were spotted in parallel on nylon filters and hybridized with type-specific probes derived form the 5 noncoding region, labeled with deoxyuridine triphosphate fluoresceine, the reaction being revealed by an enhanced chemiluminescence method (ECL, Amersham International plc, UK) on autoradiographic films. Quantitation of HCV RNA. Viral load was measured using a recently developed PCR system that includes a quantitation standard that is coamplified with the target HCV RNA (Amplicor HCV Monitor, Roche Molecular Systems). 16 RNA was extracted from 100 µl of serum and from the standard containing a known number of RNA copies by a guanidium-thiocyanate method and precipitated by isopropanol. Single-tube reverse transcription and 5 untranslated region genomic amplification was then performed in a 9600 thermal cycler (Perkin Elmer, Norwalk, CT) using rtth DNA polymerase in which AmpErase enzyme had been introduced to avoid carry-over. Amplified products were immediately denatured and transferred to probe-coated microwell plates after serial fivefold dilution. Parallel HCV-specific and quantitation standard specific hybridization was revealed by enzymatic detection and optical density measurement at a wavelength of 450 nm. The concentration of native HCV RNA was automatically calculated and was based on the ratio between the native bound HCV-RNA signal and the bound internal quantitationstandard signal. Laboratory standardization of the assay included the following evaluations: 1) sera from 4 patients (2 with high viremia and 2 with low viremia) run in decuplicate to assess the intra-assay variation; and 2) in 10 patients, HCV-RNA levels were evaluated using both serum and plasma samples obtained monthly, to assess variations of HCV-RNA determination efficiency when using sera. 17 Statistical Analysis. The Kruskal-Wallis ANOVA median test, Spearman correlation, 2 and the Fisher s exact test were used for analysis of the results. Statistical calculations were performed using the program STATISTICA (Statsoft, Inc., Tulsa, OK). HCV-RNA levels were expressed as Log-transformed values to reduce the interference of extreme values. RESULTS Serum HCV-RNA Levels Laboratory Standardization. Using a standard panel of sera at a known HCV-RNA concentration, provided by Roche Molecular Systems, the sensitivity of the assay was estimated between 10 3 and 10 4 genomes/ml. The reproducibility experiments of the HCV quantitation assay showed an intra-assay coefficient of variation ranging TABLE 1. Histological Features Observed in Chronic HCV Patients in Relation to Transaminase Profile and Viremia Levels Minimal Changes Mild Moderate Severe ALT pattern over 12 months Normal ALT Fluctuating HCV-RNA fluctuations 0.5 Log 3/3 3/15 3/12 0 NS 0.5 Log 0 12/15 9/12 1/1 NOTE. represents the difference between the maximum and minimum value of HCV RNA measured over time in each individual patient. 0.5 Log is considered the cut-off for the intrinsic variability of the assay. Abbreviations:, chronic hepatitis; NS, not significant. from 57% to 23% when sera below or above 10 4 were used, respectively. Using logarithmic transformation of the results, the standard deviation of HCV-RNA determinations per subject (one serum run in decuplicate) ranged from 0.14 to Therefore, in agreement with previously published results, 16 changes beyond 0.5 Log were considered as true fluctuations and not as intrinsic test variations. A good correlation was observed when viral load was assessed using serum or plasma samples, obtained from the same blood withdrawal and run at the same time (Spearman correlation r.82). These results are in keeping with previous findings, 16,18 while they do not confirm other data obtained with a competitive, home-made quantitative test, 17 underlying the fact that different technical approaches can influence final results. Viremia Profiles. Of the 76 HCV-infected patients, 44 had constantly normal ALT during follow-up, while 32 had fluctuating abnormal ALT. Liver biopsies were obtained from 23 patients with a normal transaminase profile and in 26 patients with elevated ALT. Table 1 shows the histological distribution in relation to transaminase and virological profiles. A significantly higher proportion of patients with a normal transaminase profile had minimal liver lesions or mild chronic hepatitis, as compared with patients with fluctuating ALT, who showed more active histology. The rate of fluctuations beyond the variability of the assay was similar in patients with mild or moderate chronic hepatitis. All 3 patients with minimal changes showed stable viremic levels over time. Relation to HCV Genotype. Overall, 38 patients were infected with genotype 1, 14 were infected with genotype 2, and 2 patients were infected with genotype 3. HCV carriers infected with genotype 1 showed higher levels of viremia than those infected with genotype 2 or genotype 3 (P.001), as shown in Table 2. The observed differences are likely the result of the underestimation of HCV-RNA load in viral types 2 and 3 by the version of the assay used. 6,18 Genotype TABLE 2. Viral Load in Relation to Infecting Genotype Patients Mean SD Median P Range Genotype Genotype Genotype
3 HEPATOLOGY Vol. 29, No. 2, 1999 PONTISSO ET AL. 587 TABLE 3. Maximum Changes of HCV RNA Observed in Serum During Follow-up in HCV-Infected Patients Monthly Sampling Yearly Sampling Cases (mean SD) (range) Cases (mean SD) (range) ALT profile Normal ALT * Elevated ALT Genotype Genotype Genotype Genotype Liver histology Minimal changes Mild Moderate Severe Abbreviation: chronic hepatitis. *vs P.004. Viral Fluctuations Over Time in Relation to Clinical Profile. Serial determinations of viral load were performed in 22 patients with yearly collected serum samples (10 with normal ALT and 12 with elevated ALT), while for 54 additional patients (28 with normal ALT and 26 with elevated ALT), monthly collected serum samples were studied. Table 3 shows individual changes of viremia, expressed as the maximum Log difference detected during the observation period, in relation to transaminase profile, infecting genotype, and histological findings. A significant difference was identified in monthly tested samples between patients with a normal ALT profile compared with patients with elevated ALT. Infecting genotype and overall histology did not show any influence on viremia profiles, although all the patients with minimal lesions had low fluctuations of HCV RNA, but their small number did not allow any definitive conclusion. The variability of HCV-RNA values in serial measurements of each patient over time is reported in Fig. 1. In patients with normal ALT, monthly testing showed changes 1 Log in the majority of the patients, 23% of them being below the intrinsic variability of the assay, while larger changes were observed in patients with fluctuating ALT. These features were not detectable in patients tested yearly, likely because long-term viral kinetics revealed that in all the patients examined monthly, a maximum of three peaks of viremia, defined as 50% increase, were experienced over 1 year. This occurred in 59% of the patients, while 33% experienced two HCV-RNA peaks, and only 8% had none or one peak. The high likelihood of testing inter-spikes levels of HCV RNA when comparing single points per each year most likely explains this finding. Temporal behavior of viremia in relation to ALT profile is described in Fig. 2. HCV-RNA fluctuations above the assay variability were observed in 77% of the patients with normal ALT profile and in 92% of the patients with abnormal ALT. In this latter group, viral profile was synchronous with transaminase behavior in 38% of the patients, while in 62% of them, the two parameters were not synchronized (Fig. 3C and 3D). DISCUSSION Fluctuations over time of HCV replication during the course of chronic HCV infection is a relevant issue that has not been definitely explored. Several clinical relations with replication activity of the virus, including grade of disease and response to antiviral drugs, have been based on singletime-point determinations of viremia. 10,19-28 To date, conflicting results have been reported on long-term monitoring of viral replication. Different time intervals, ranging from diurnal to monthly determinations, have been evaluated using different methods of measurement, and discordant conclu- FIG. 1. Distribution of the difference between the maximum and minimum value ( ) of HCV RNA in samples tested over time in individual patients. The median value for each group is represented by a solid bar. The gray zone indicates the range of intrinsic assay variability.
4 588 PONTISSO ET AL. HEPATOLOGY February 1999 FIG. 2. Median values of biochemical profiles in relation to HCV-RNA levels over time observed in patients studied monthly with a normal (A) and abnormal (B) ALT profile. sions might result from the above-mentioned variables. No fluctuations were reported when daily to monthly analysis over 3 months was performed using the branched-dna assay, 11 while wide monthly fluctuations have been described over 6 months using a competitive reverse-transcription PCR technique. 8 In this multicenter study, viremia has been monitored in a large number of untreated patients both on a monthly and a yearly basis, and the majority of the samples has been prospectively collected, following standard criteria of specimen handling and storage conditions. Monthly measurement of HCV RNA revealed that the majority of the patients experienced, on average, three peaks of viremia over 1 year, with a median change of absolute value of about 1 Log, while the remaining patients had a lower frequency of HCV-RNA flares. These findings indicate that a careful viral replication profile can be obtained only by monthly testing, because longer time intervals could miss viremia fluctuations. Monthly variations of HCV RNA were significantly lower in patients with a normal transaminase profile, as compared with those with abnormal ALT, suggesting a relationship between the two parameters. Comparison of ALT and HCV-RNA patterns in patients with fluctuating ALT revealed that in the majority of the patients, fluctuations were asynchronous (i.e., two ALT flares and three HCV-RNA peaks per year). While no impairment of HCV replication seems to occur in patients with normal transaminases, hepatocyte lysis observed in patients with fluctuating ALT could hamper viral replicative activity. As a consequence, a single determination of HCV-RNA level in patients with abnormal ALT does not seem adequate to classify individual patients as high or low viremic. It has been repeatedly reported that low viral loads are associated with better response to interferon, either alone or in combination with ribavirin ,29 As a result of the observed viral fluctuations, the suggestion of waiting to start treatment until the patients have lower viremia to increase the response rates could arise. However, prospective trials are needed to specifically address this point. Liver histology did not show any significant correlation with replication activity of the virus, but in the study population, extreme histological features, including minimal changes and active cirrhosis, were not adequately represented. Further studies are required to draw conclusions on the relationship between viral replication profile and liver disease activity at the histological level. When patients were divided according to the infecting genotype, similar fluctuations were detected in all groups, although absolute values of viremia observed in cases infected with genotype 1 were higher than those detected in patients infected with genotype 2 and with genotype 3. This is likely a result of a better efficiency of detection of genotype 1 by the current version of the assay. 6,18 In conclusion, long-term monitoring of viral replication showed that HCV RNA is relatively stable over time in asymptomatic HCV carriers, while a low number of viremic flares can occur over a year in patients with biochemical activity of liver disease. FIG. 3. Examples of ALT and HCV-RNA behavior in individual patients with constantly normal ALT (A, B) and in patients with fluctuating ALT (C, D), prospectively studied monthly for 12 months.
5 HEPATOLOGY Vol. 29, No. 2, 1999 PONTISSO ET AL. 589 Acknowledgment: The authors are deeply greateful to Professors A. Alberti, F. Bonino, M. Colombo, and A. Craxì for their substantial contribution in the design of the study and in the discussion of the results. REFERENCES 1. Simmonds P, Zhang LQ, Watson HG, Rebus S, Ferguson ED, Balfe P, Leadbetter GH, et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990;336: Kaneko S, Murakami S, Unoira M, Kobayashi K. Quantitation of hepatitis C virus RNA by competitive polymerase chain reaction. J Med Virol 1992;37: Young KK, Archer JJ, Yokosuka O, Omata M, Resnick RM. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing. J Clin Microbiol 1995;33: Kievitis T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adrianse H, Malek L, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991;35: Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 1991;24: Ohno T, Lau JYN. The Gold Standard accuracy, and the current concepts: hepatitis C virus genotypes and viremia. HEPATOLOGY 1996;24: Gretch DR, dela Rosa C, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlation and clinical implications. Ann Intern Med 1995;123: Giostra F, Francesconi R, Groff P, Manzin A, Solforosi L, Lari F, Ballardini G, et al. Wide fluctuation of plasmatic HCV genome levels in serial samples of patients before interferon (IFN) treatment [Abstract]. HEPA- TOLOGY 1995;22:341A. 9. Gordon SC, Khan BA, Dmuchowski CF, Kodali VP, Silverman AL. The spontaneous fluctuation of viremia over time in untreated patients with chronic type C hepatitis [Abstract]. HEPATOLOGY 1995;22:341A. 10. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viraemia, liver function tests and histology. HEPATOLOGY 1996;24: Nguyen TT, Sedghi-Vaziri A, Wilkers LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996;3: Hollingsworth RC, Sillekens P, van Deursen P, Neal KR, Irving WL and the Trent HCV Study Group. Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. J Hepatol 1996;25: Gerken G. Pontisso P, Roggendorf M, Rumi MG, Simmonds P, Trepo C, Zeuzem S, et al. Clinical evaluation of a single reaction, diagnostic PCR assay for the detection of hepatitis C virus (HCV) RNA. J Hepatol 1996;24: Pontisso P, Ruvoletto MG, Nicoletti M, Tisminetzky S, Gerotto M, Levrero M, Artini M, et al. Distribution of three major hepatitis C virus genotypes in Italy. A multicenter study of 495 patients with chronic hepatitis C. J Viral Hepat 1995;2: Pontisso P, Gerotto M, Ruvoletto MG, Fattovich G, Chemello L, Tisminetzky S, Baralle F, et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. J Med Virol 1996;48: Miskovsky EP, Carrella AV, Gutekunst K, Sun C-A, Quinn TC, Thomas DL. Clinical characterization of a competitive PCR assay for quantitative testing of hepatitis C virus. J Clin Microbiol 1996;34: Manzin A, Bagnarelli P, Menzo S, Giostra F, Brugia M, Francesconi R, Bianchi FB, et al. Quantitation of hepatitis C virus genome molecules in plasma samples. J Clin Microbiol 1994;32: Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus load among individuals infected with hepatitis C virus (HCV) genotypes 1,2, and 3 by Quantiplex HCV RNA assay version 1 and 2, Roche Monitor Assay, and an in-house limiting dilution method. J Clin Microbiol 1997;35: Busch MP, Wilber JC, Johnson P, Tobler L, Evans CS. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1995;32: Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. HEPATOLOGY 1993;17: Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341: Gretch D, Corey L, Wilson J, dela Rosa C, Willson R, Carithers Jr R, Busch M, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high titer viremia correlates with advanced stage of disease. J Infect Dis 1994;169: Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. HEPATOLOGY 1994; Martinot-Peignoux M, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M, Wild AM, et al. Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-hcv positive blood donors. J Hepatol 1994;20: Yamada GR, Takatani F, Kishi M, Takahashi M, Doi T, Tsuji T, Shin S, et al. Efficacy of interferon alfa therapy in chronic hepatitis C depends primarily on hepatitis C virus RNA level. HEPATOLOGY 1995;22: Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. HEPATOLOGY 1995;22: Magrin S, Craxì A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, Volpes R, et al. HCV vireamia is more important than genotype as predictor of response to interferon in Sicily (Southern Italy). J Hepatol 1996;25: Smith DB, Davidson F, Yap PL, Brown H, Kolberg J, Detmer J, Urdea M, et al. Levels of hepatitis C virus in blood donors infected with different viral genotypes. J Infect Dis 1996;173: Reichard O, Norkrans G, Frydén A, Braconier JH, Sonnerborg A, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon -2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
Papers. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA
J Clin Pathol 1999;52:807 811 807 Papers Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical College Hospital, No 100, Shih-Chuan 1st Rd, Kaohsiung, Taiwan, Republic of China M-L
More informationSequential Serum Hepatitis C Viral RNA Levels Longitudinally Assessed by Branched DNA Signal Amplification
Sequential Serum Hepatitis C Viral RNA Levels Longitudinally Assessed by Branched DNA Signal Amplification STUART C. GORDON, 1,2 PETER J. DAILEY, 3 ANN L. SILVERMAN, 1,2 BILAL A. KHAN, 1 VALLISTRAM P.
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE CORRELATION BETWEEN SERUM AMINOTRANFERASE LEVELS AND HCV RNA LOAD IN HEPATITIS C VIRUS RELATED CHRONIC LIVER DISEASE. SINGH J 1, CHHINA
More informationSerum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features
856 Department of Clinical and Experimental Medicine, University of Padova, Italy L De Moliner P Pontisso G L De Salvo L Cavalletto L Chemello A Alberti Correspondence to: Dr P Pontisso, Clinica Medica
More informationComparison of Quantitative HCV RNA Assays in Chronic Hepatitis C
MICROBIOLOGY AND INFECTIOUS DISEASE Original Article Comparison of Quantitative HCV RNA Assays in Chronic Hepatitis C SHERAJ JACOB, MD, DEBORAH BAUDY, ELIZABETH JONES, LIZHE XU, PhD, ANDREW MASON, MBBS,
More informationPerformance of an automated system for quantification of hepatitis C virus RNA
Journal of Virological Methods 86 (2000) 55 60 www.elsevier.com/locate/jviromet Performance of an automated system for quantification of hepatitis C virus RNA Anne Marie Roque Afonso a, *, Josiane Didier
More informationGenotype Dependence of Hepatitis C Virus Load Measurement in Commercially Available Quantitative Assays
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1999, p. 2525 2532 Vol. 37, No. 8 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Genotype Dependence of Hepatitis C
More informationPerformance Characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, Version 2.0
Clinical Chemistry / EVALUATION OF QUANTITATIVE HEPATITIS C VIRUS ASSAY Performance Characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, Version 2.0 Maria Erali, MS, 1 Edward R. Ashwood,
More informationTechnical Bulletin No. 162
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationInterferon alfa therapy is now widely recommended for
GASTROENTEROLOGY 1999;117:408 413 Interferon-Ribavirin for Chronic Hepatitis C With and Without Cirrhosis: Analysis of Individual Patient Data of Six Controlled Trials SOLKO W. SCHALM,* OLA WEILAND, BETTINA
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More informationStandardization of Hepatitis C Virus RNA Quantification
Standardization of Hepatitis C Virus RNA Quantification JEAN-MICHEL PAWLOTSKY, 1,2 MAGALI BOUVIER-ALIAS, 1 CHRISTOPHE HEZODE, 3 FRANCOISE DARTHUY, 1 JOCELYNE REMIRE, 1 AND DANIEL DHUMEAUX 2,3 It was recently
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationHCV HIV +*+ Human immunodeficiency virus HIV hepatitis C virus HCV HIV HCV HCV HIV HIV
,**- The Japanese Society for AIDS Research The Journal of AIDS Research +0 HIV HCV + + + + + + + + +, +, :HCV HIV HAART / : +*+ +*0,**- Human immunodeficiency virus HIV hepatitis C virus HCV HIV,* HCV
More informationProspective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2001, p. 4005 4012 Vol. 39, 11 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.11.4005 4012.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationEFFICACYAND SAFETY OF INTERFERON ALPHA 2 B PLUS RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C PATIENTS WITH PULMONARY TUBERCULOSIS
ORIGINAL ARTICLE EFFICACYAND SAFETY OF INTERFERON ALPHA 2 B PLUS RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C PATIENTS WITH PULMONARY TUBERCULOSIS Rukhsana Javed Farooqi, Javed Iqbal Farooqi Department
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationInterferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1
Title Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1 Author(s) Hui, CK; Yuen, MF; Sablon, E; Chan, AOO; Wong, BCY; Lai, CL Citation Journal Of Infectious
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationPegylated interferons (peginterferons) represent the
Viral Kinetics in Genotype 1 Chronic Hepatitis C Patients During Therapy With 2 Different Doses of Peginterferon Alfa-2b Plus Ribavirin Maria Buti, 1 Francisco Sanchez-Avila, 1 Yoav Lurie, 2 Carlos Stalgis,
More informationJOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2000, p Vol. 38, No. 11. Copyright 2000, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2000, p. 4171 4179 Vol. 38, No. 11 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Improved Version 2.0 Qualitative
More informationRetrospective analysis of chronic hepatitis C in untreated patients with nonlinear mixed effects model
J. Biomedical Science and Engineering, 2008, 1 8-90 Retrospective analysis of chronic hepatitis C in untreated patients with nonlinear mixed effects model Jian Huang 1, Kathleen O Sullivan 1, John Levis
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationLaboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.
000000 00000 0000 000 00 0 bdna () 00000 0000 000 00 0 Nuclisens () 000 00 0 000000 00000 0000 000 00 0 Amplicor () Comparison of Amplicor HIV- monitor Test, NucliSens HIV- QT and bdna Versant HIV RNA
More informationEvaluation of Interferon Treatment in Cirrhotic Patients with Hepatitis C
Evaluation of Interferon Treatment in Cirrhotic Patients with Hepatitis C Tatsuya IDE, Michio SATA, Hiroshi SUZUKI, Shiroh MURASHIMA, Ichiroh MIYAJIMA, Miki SHIRACHI and Kyuichi TANIKAWA The Second Department
More informationNatural Fluctuations of Hepatitis C Viral Load in a Homogeneous Patient Population: A Prospective Study
Natural Fluctuations of Hepatitis C Viral Load in a Homogeneous Patient Population: A Prospective Study LIAM FANNING, 1 ELIZABETH KENNY-WALSH, 1 JOHN LEVIS, 1 KINGSHUK ROY CHOUDHURY, 2 BRIDIN CANNON, 1
More informationFully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan System,
Journal of Clinical Virology 38 (2007) 326 333 Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan System, Dorothea Sizmann,
More informationRelative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection
PO Box 2345, Beijing 123, China World J Gastroenterol 25;11(43):6848-6852 www.wjgnet.com World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com E L S E V I E R 25 The WJG Press and Elsevier Inc.
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationThe importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B
The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B LIVER Kaan Demirören, Halil Kocamaz, Yaşar Doğan Department
More informationYun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, Woo Jin Chung, and Jae Seok Hwang
The Korean Journal of Hepatology 2012;18:41-47 http://dx.doi.org/10.3350/kjhep.2012.18.1.41 pissn: 1738-222X eissn: 2093-8047 Original Article Rapid normalization of alanine aminotransferase predicts viral
More informationMedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article
HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationDeterminants of the Quantity of Hepatitis C Virus RNA
844 Determinants of the Quantity of Hepatitis C Virus RNA David L. Thomas, 1,2 Jacquie Astemborski, 2 David Vlahov, 2,3 Steffanie A. Strathdee, 2 Stuart C. Ray, 1 Kenrad E. Nelson, 2 Noya Galai, 2 Karen
More informationAutomated Quantitative Analysis of Hepatitis B Virus DNA by Using the Cobas Amplicor HBV Monitor Test
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1999, p. 2793 2797 Vol. 37, No. 9 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Automated Quantitative Analysis of
More informationHEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS
HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS I. Qattan Centres for Hepatology, Royal Free & University College Medical School, London V. Emery Department of Virology, Royal Free & University
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationMonitoring of HCV RNA. Hepatitis C Requirements of Antiviral Therapy Monitoring
Monitoring of HCV RNA Hepatitis C Requirements of Antiviral Therapy Monitoring Hepatitis C Requirements of Antiviral Therapy Monitoring Author: Ute Hofmann,, Konrad-Zuse-Str. 1, 07745 Jena, Germany Beatrix
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationConventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3
ORIGINAL ARTICLE Conventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3 Javed Iqbal Farooqi and Rukhsana Javed Farooqi* ABSTRACT Objective: To determine the efficacy
More informationCHRONIC HEPATITIS C VIRUS
CLINICAL REVIEW CLINICIAN S CORNER Molecular Diagnostics of Hepatitis C Virus Infection A Systematic Review John D. Scott, MD, MSc David R. Gretch, MD, PhD See also Patient Page. CME available online at
More informationHepatitis C virus (HCV) is a major cause of posttransfusion
Molecular Testing in the Diagnosis and Management of Hepatitis C Virus Infection Raymond P. Podzorski, PhD Objectives. To review hepatitis C virus (HCV), describe the types of molecular-based tests available
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationThe Relationship of Histologic Activity to Serum ALT, HCV genotype and HCV RNA titers in Chronic Hepatitis C
J Korean Med Sci 1; 16: 585-91 ISSN 111-8934 Copyright The Korean Academy of Medical Sciences The Relationship of Histologic Activity to Serum ALT, HCV genotype and HCV RNA titers in Chronic Hepatitis
More informationon October 4, 2018 by guest
JCM Accepts, published online ahead of print on 3 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.01249-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Title: Performance of
More informationP0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationHuman diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family
Human diagnostics Better be Sure: Quantify HDV & HBV viral load. RoboGene product family 2 RoboGene Product Family Improved patient management: Standardized monitoring of HBV DNA and HDV RNA viral load.
More informationORIGINAL INVESTIGATION. Age-Related Response to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection
ORIGINAL INVESTIGATION Age-Related to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection Jun Hayashi, MD, PhD; Yasuhiro Kishihara, MD; Kumiko Ueno, MD; Kouzaburo Yamaji,
More informationInternational Journal of Pharma and Bio Sciences DETECTION OF HEPATITIS B SURFACE ANTIGEN USING ELISA AND REAL TIME PCR ABSTRACT
Research Article Biotechnology International Journal of Pharma and Bio Sciences ISSN 0975-6299 DETECTION OF HEPATITIS B SURFACE ANTIGEN USING ELISA AND REAL TIME PCR ALI MOHAMMED ABDUL MOHSEN Indian academy
More informationW ith an estimated million people worldwide
141 ORIGINAL ARTICLE Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan C-Y Dai,
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationHepatitis C Virus Diagnosis and Testing
Hepatitis C Virus Diagnosis and Testing Mel Krajden, MD, FRCPC Development of serological and nucleic acid testing (NAT) has revolutionized hepatitis C virus (HCV) diagnosis. Although third generation
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationQUANTITATIVE HEPATITIS C VIRUS (HCV) RNA
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:
More informationApproximately 200 million individuals worldwide
Triphasic Decline of Hepatitis C Virus RNA During Antiviral Therapy Harel Dahari, Ruy M. Ribeiro, and Alan S. Perelson When patients chronically infected with hepatitis C virus (HCV) are placed on antiviral
More informationBringing quantitative HBsAg to the US provider, drug development and patient network
Bringing quantitative HBsAg to the US provider, drug development and patient network Presenter Robert G Gish MD Adjunct Professor, Stanford University Medical Director HBV Foundation HBV Forum 3 October
More informationStrengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2004, p. 421 425 Vol. 42, No. 1 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.1.421 425.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Strengths
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationHepatitis C Virus Genotype 2 may not be detected by the Cobas AmpliPrep/Cobas. TaqMan HCV Test, version 1.0
JCM Accepts, published online ahead of print on 25 September 2013 J. Clin. Microbiol. doi:10.1128/jcm.02102-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Hepatitis C Virus
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere q HIV-1/2 Detect WHO reference number: PQDx 0226-032-00 Alere q HIV-1/2 Detect with product codes 270110050, 270110010 and 270300001,
More informationINTERFERON ALFA-2b ALONE OR WITH RIBAVIRIN FOR THE TREATMENT OF RELAPSE OF CHRONIC HEPATITIS C
ALFA-2b ALONE OR WITH RIBAVIRIN FOR THE TREATMENT OF RELAPSE OF CHRONIC HEPATITIS C ALFA-2b ALONE OR IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF RELAPSE OF CHRONIC HEPATITIS C GARY L. DAVIS, M.D.,
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Hepatol Int (2013) 7:88 97 DOI 10.1007/s12072-012-9343-x ORIGINAL ARTICLE Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative
More informationPolymerase Chain Reaction RNA Assays To Establish
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1992, p. 2145-2149 0095-1137/92/082145-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 30, No. 8 Use of Aminotransferase, Hepatitis C Antibody,
More informationHIV-1 Viral Load Real Time (RG)
-1 Viral Load Real Time (RG) Real Time RT-PCR type 1 RNA quantification assay MSP Reg. pending Valdense 3616. 11700. Montevideo. Uruguay. phone (598) 2 336 83 01. Fax (598) 2 336 71 60. Info@atgen.com.uy
More informationIs an À la Carte Combination Interferon Alfa-2b Plus Ribavirin Regimen Possible for the First Line Treatment in Patients With Chronic Hepatitis C?
Is an À la Carte Combination Interferon Alfa-2b Plus Ribavirin Regimen Possible for the First Line Treatment in Patients With Chronic Hepatitis C? THIERRY POYNARD, 1 JOHN MCHUTCHISON, 2 ZACHARY GOODMAN,
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationRelation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection
Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection xxxxxxxxxxxxxxx Özgür Günal 1, Şener Barut 1, İlker Etikan 2, Fazilet Duygu 1, Umut Tuncel 3, Mustafa
More informationLong term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy
154 LIVER Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy B J Veldt, G Saracco, N Boyer, C Cammà, A Bellobuono, U Hopf, I Castillo,
More informationCirrhosis secondary to hepatitis C virus (HCV) infection
The Use of Hepatitis C Viral RNA Levels in Liver Tissue to Distinguish Rejection From Recurrent Hepatitis C Michelle J. Gottschlich, * Kay L. Aardema, Eileen M. Burd, Raouf E. Nakhleh, Kimberly A. Brown,
More informationReceived 31 August 2004/Returned for modification 13 October 2004/Accepted 24 February 2005
JOURNAL OF CLINICAL MICROBIOLOGY, June 2005, p. 2590 2597 Vol. 43, No. 6 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.6.2590 2597.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationDiagnosis of Acute HCV Infection
Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson
More informationFeature. Downloaded from by guest on 06 November 2018
Hepatitis C Virus: Epidemiology, Diagnosis, and Patient Management Peter P. Chou, PhD, DABCC, FACB (Quest Diagnostics Nichols Institute, Chantilly, VA) DOI: 10.1309/BNK8PH8FEPJ0VCH2 Laboratory photo courtesy
More informationPerformance of Version 2.0 of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2010, p. 3641 3647 Vol. 48, No. 10 0095-1137/10/$12.00 doi:10.1128/jcm.01306-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Performance
More informationReceived 20 February 1996/Returned for modification 18 April 1996/Accepted 19 June 1996
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1996, p. 2191 2195 Vol. 34, No. 9 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Detection of Hepatitis C Virus by PCR in Second-Generation
More informationIdentifying potential HCV drug leads by small molecule screening.
Identifying potential HCV drug leads by small molecule screening. Ivar S. Helgason Background Hepatitis C (HCV) is a viral infection of the liver which had been referred to as parenterally transmitted
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More informationTreatment of Chronic Hepatitis C in Non-Responders
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Chronic Hepatitis C in Non-Responders Jay H. Hoofnagle INTRODUCTION The treatment of chronic hepatitis C has evolved markedly over
More informationHepatitis C: A Hepatologist s Approach to an Infectious Disease
CLINICAL PRACTICE Ellie J. C. Goldstein, Section Editor INVITED ARTICLE Hepatitis C: A Hepatologist s Approach to an Infectious Disease Peter M. Rosenberg Department of Medicine, St. John s Health Center,
More informationReceived 26 August 1997/Returned for modification 18 December 1997/Accepted 20 January 1998
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1998, p. 872 877 Vol. 36, No. 4 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Different Hepatitis C Virus (HCV) RNA Load Profiles Following
More informationOptimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
More informationProtection against persistence of hepatitis C
Mechanisms of disease Protection against persistence of hepatitis C Shruti H Mehta, Andrea Cox, Donald R Hoover, Xiao-Hong Wang, Qing Mao, Stuart Ray, Steffanie A Strathdee, David Vlahov, David L Thomas
More informationMolecular Diagnosis Future Directions
Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationChronic hepatitis B (CHB) infection is a large
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 2, 2016 Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
More information: TP6.3 g dl, Alb4.3 g dl, GOT17 IU l, GPT26 IU l,
5 Vol. 34, pp. 5 23, 2006 C IFN 0 2 : 8 4 20 63 986 990 C 993 S7 C A F2 IFN IFNa2a 9MIU 24W HCV-RNA 995 2 F HCV-RNA IFN 0 2004 5 S8 20 mm CT SPIO-MRI 6 TP6.3 g dl, Alb4.3 g dl, GOT7 IU l, GPT26 IU l, g-gtp40
More informationA Genotype-Independent Real-Time PCR Assay for Quantification of Hepatitis B Virus DNA
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2007, p. 553 558 Vol. 45, No. 2 0095-1137/07/$08.00 0 doi:10.1128/jcm.00709-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. A Genotype-Independent
More informationCaution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy Anjana A. Pillai, Emory University Frank A Anania, Emory University Brian L. Pearlman, Emory University
More informationLymphoblastoid interferon alfa treatment in
152 Department of Paediatrics, University of Naples 'Federico II', Italy R Iorio P Pensati S Porzio I Fariello S Guida A Vegnente Correspondence and reprint requests to: Dr Raffaele Iorio, Dipartimento
More informationResearch Article Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients
Gastroenterology Research and Practice Volume 2009, Article ID 812140, 5 pages doi:10.1155/2009/812140 Research Article Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More information